Clinical guideline
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update
J Clin Oncol · 2026
Studies and guidelines: Stomach cancer
32 items with a structured summary · Stomach cancer: the complete guide
Clinical guideline
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
J Natl Compr Canc Netw · 2025
Clinical guideline
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Ann Oncol · 2022
Clinical guideline
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Gut · 2022
41 experts from 29 countriesNumber of participating experts
Clinical trial · Phase 3
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
Ann Oncol · 2026
HR 0.71Overall survival in CPS ≥5
Clinical trial · Phase 3
Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study
ESMO Open · 2026
12.9 vs 11.5 monthsMedian overall survival in all patients
Clinical trial · Phase 3
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
N Engl J Med · 2025
14.7 vs 11.4 monthsMedian overall survival
Other
Pembrolizumab in HER2-Positive Gastric Cancer
N Engl J Med · 2024
Clinical trial · Phase 3
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Lancet · 2023
10.0 vs 8.1 monthsMedian progression-free survival (second interim analysis)
Other
Trend of geographical distribution of stomach cancer in Iran from 2004 to 2014
BMC Gastroenterol · 2022
49,907 (70.0%)Proportion of male patients
Clinical trial · Phase 3
Family History of Gastric Cancer and Helicobacter pylori Treatment
N Engl J Med · 2020
1.2% vs 2.7%Incidence of gastric cancer
Review article
Gastric cancer
The Lancet · 2020
Fifth most common cancer in the worldRank of gastric cancer in incidence
Observational study
Opium use and subsequent incidence of cancer: results from the Golestan Cohort Study
Lancet Glob Health · 2020
HR 1.40All cancers
Clinical trial · Phase 2
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
N Engl J Med · 2020
51% vs 14%Objective response
Observational study
Trends in the Incidence of Stomach Cancer in Golestan Province, a High-risk Area in Northern Iran, 2004–2016
Arch Iran Med · 2020
2964 patientsTotal number of registered patients
Clinical trial · Phase 2/3
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Lancet · 2019
50 months vs 35 monthsMedian overall survival
Clinical trial · Phase 3
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Lancet · 2010
13.8 vs 11.1 monthsMedian overall survival
Clinical trial
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
N Engl J Med · 2008
0.86HR for death: capecitabine vs fluorouracil
Clinical trial · Phase 2/3
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
JCO · 2006
32% risk reduction with DCF vs CFTime to progression (TTP)
Clinical trial · Phase 3
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Lancet Oncol · 2014
9.6 vs 7.4 monthsMedian overall survival
Other · Phase 2
First CAR T-Cell Therapy Approved for Solid Tumors
Cancer Discovery · 2026
Improvement reported (no figures in the abstract)Progression-free survival and overall survival
Other
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer
J Hematol Oncol · 2026
All three patientsClinical and radiological benefit and durable control of peritoneal disease
Clinical trial · Phase 3
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
The Lancet · 2026
Hazard ratio 0.78 (95% CI 0.63–0.96) in favour of durvalumabOverall survival (OS) in the ITT population
Other
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
Nat Rev Clin Oncol · 2025
Clinical trial
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
Lancet · 2025
3.25 vs 1.77 monthsMedian progression-free survival
Other
KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
J Clin Oncol · 2025
Improved by adding pembrolizumab to chemotherapyPathological complete response rate in KEYNOTE-585
Clinical trial · Phase 1
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Nat Med · 2024
32.4 monthsMedian follow-up (from apheresis)
Clinical trial · Phase 3
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
Nat Med · 2023
8.21 vs 6.80 monthsMedian progression-free survival
Clinical trial · Phase 3
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Lancet · 2023
10.61 vs 8.67 monthsMedian progression-free survival
Clinical trial · Phase 3
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
N Engl J Med · 2025
67.4% vs 58.5%Two-year event-free survival
Clinical trial · Phase 3
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Lancet Oncol · 2023
12.9 vs 11.5 monthsMedian overall survival (ITT)
Clinical trial · Phase 3
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Lancet · 2021
14.4 vs 11.1 monthsMedian overall survival (CPS ≥5)
Nothing found.